EP.07E.04 Efficacy and Safety of Anlotinib Plus EGFR-TKIs in Slowly or Locally Progressing NSCLC after Adjuvant Therapy with EGFR-TKIs
Back to course
Pdf Summary
Asset Subtitle
Jiayue Ye
Meta Tag
Speaker Jiayue Ye
Topic Early-Stage Non-small Cell Lung Cancer
Keywords
anlotinib
EGFR-TKIs
non-small cell lung cancer
NSCLC
tyrosine kinase inhibitor
EGFR mutations
progression-free survival
overall survival
adverse events
treatment resistance
Powered By